ClinicalTrials.gg
CompletedNCT04069156Updated Mar 27, 2025Results posted

The ARIES HeartMate 3 Pump IDE Study

An interventional study of LVAD Implant and Aspirin 100mg in Heart Failure, sponsored by Abbott Medical Devices. Completed at 51 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-27.

Sponsored by Abbott Medical Devices (part of Abbott) · Not applicable, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
628
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 120 studies in Heart Failure by Abbott — 6 open to participants now, 9 under way, none of them phase 3. Heart Failure · Abbott.

Enrollment
13th of 72
628 · median 136
Started
2020
with 3 others
No phase
62 of 120
2 open now
Registered
105th of 120
by date

Among the 120 studies in Heart Failure by Abbott, this one is the 13th largest by enrollment of the 72 interventional ones that give a count, is one of 4 that started in 2020, is one of 62 with no phase, and was the 105th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Open to participants now

6 of the 120 studies in Heart Failure by Abbott are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies in Heart Failure by Abbott, or all of them as a file.
02

Study summary

Prospective, randomized, double-blinded, placebo-controlled clinical investigation of advanced heart failure patients treated with the HM3 with two different antithrombotic regimens: vitamin K antagonist with aspirin versus vitamin K antagonist with placebo

Read the detailed description

This clinical investigation is a prospective, randomized, double-blinded, placebo-controlled study of advanced heart failure patients treated with the HM3 with two different antithrombotic regimens: vitamin K antagonist with aspirin versus vitamin K antagonist with placebo.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • heart failure
  • ventricular assist device
  • LVAD
  • aspirin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject will receive the HeartMate 3 per standard of care (SOC) in accordance with the approved indications for use in the country of implant.
  2. Subject will receive the HeartMate 3 as their first durable VAD.
  3. Subject must provide written prior to any clinical investigation related procedure.
  4. In female patients of child bearing capability, subject will not be currently pregnant or breastfeeding and on appropriate .

Exclusion criteria

Exclusion Criteria:

  1. Post-implant additional temporary or permanent mechanical circulatory support (MCS).
  2. Investigator mandated antiplatelet therapy for other conditions (including mandated presence or absence of antiplatelet agent).
  3. Patients who are nil per os (NPO) post-implant through day 7.
  4. Subjects with a known allergy to acetylsalicylic acid (aspirin).
  5. Participation in any other clinical investigation(s) involving an MCS device, or interventional investigation(s) likely to confound study results or affect study outcome.
  6. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
628 participants (actual)

Study arms

  • Placebo comparator
    Placebo Arm

    LVAD Patients on the placebo arm will be given placebo medication

    Device: LVAD Implant · Drug: Placebo oral tablet

  • Active comparator
    Active Arm

    LVAD Patients on the active arm will be given 100mg Aspirin

    Device: LVAD Implant · Drug: Aspirin 100mg

Interventions

  • DeviceLVAD Implant

    Subjects will undergo Heartmate 3 LVAD implant prior to randomization

  • Subjects will be randomized to either Placebo or Aspirin post implant.

  • DrugPlacebo oral tablet

    Subjects will be randomized to either Placebo or Aspirin post implant

06

What researchers measure

Primary outcomes

  1. Powered Primary Endpoint of Survival Free of Non-surgical Major Hemocompatibility Related Adverse Events

    The primary end point was a composite of survival free of non-surgical major hemocompatibility related adverse events (specifically stroke, pump thrombosis, major non-surgical bleeding, and arterial peripheral thromboembolism) at 1-year post implant.

    Time frame: 12 Months

Secondary outcomes

  1. Rates of Non-surgical Major Hemorrhagic Events

    The rate of non-surgical hemorrhagic events were compared between the two arms of the study. Non-surgical Major Hemorrhagic events: Hemorrhagic event rate per patient year was calculated by dividing all non-surgical bleeding events and hemorrhagic stroke events by the cumulative years of study exposure.

    Time frame: Through Study Completion with a Median Follow up of 14 Months

  2. Rates of Bleeding Events

    The bleeding rate was calculated by dividing the number of bleeding events by the cumulative duration of study exposure (years of support).

    Time frame: Through Study Completion with a Median Follow up of 14 Months

  3. Rates of Non-surgical Major Thrombotic Events

    The rates of non-surgical major thrombotic events was compared between the two arms of the study. The thrombotic event rate per patient year was calculated by dividing the number of non-surgical ischemic strokes, pump thrombosis and arterial peripheral thromboembolic events by the cumulative years of study exposure

    Time frame: Through Study Completion with a Median Follow up of 14 Months

  4. Rates of Stroke

    The stroke rate was calculated based on the number of strokes experienced by subjects, 14 days or more after device implant, and while on their treatment assignment, divided by the cumulative duration of study exposure (years of support).

    Time frame: Through Study Completion with a Median Follow up of 14 Months

  5. Survival Rates

    The overall survival rate was analyzed using a Kaplan-Meier analysis and the treatment groups were compared using log-rank test. Survival was calculated starting at 14 days post implant.

    Time frame: 24 Months

  6. Risk of Non-Surgical Bleeding Events

    Risk of non-surgical bleeding events was analyzed using a Kaplan-Meier analysis. The treatment groups were compared using a log-rank test.

    Time frame: 24 Months

Other outcomes

  1. Rate of Rehospitalization

    This study assessed changes in the rehospitalization as a result of removal of antiplatelet therapy from the antithrombotic regimen.

    Time frame: Through Study Completion with a Median Follow up of 14 Months

  2. Economic Cost Implications - Total Estimated Cost for Bleeding Events (CMS Cost Basis)

    Cost of bleeding episodes was calculated based on a previously published economic model, adjusted for inflation using the US Bureau of Labor Statistics Medical Consumer Price Index. To ensure uniformity in care practices and relevance of the previously published model, only US subjects were included.

    Time frame: 12 Months

  3. Economic Cost Implications - Average Cost Per Bleeding Event

    These values were derived by dividing the total estimated cost for bleeding events by the number of events to determine the average cost per bleeding event. Consequently, a measure of dispersion is not available for these outcomes.

    Time frame: 12 Months

  4. Economic Cost Implications - Average Cost Per Study Patient Over the First-year Post-implant

    These values were derived by dividing the total estimated cost for bleeding events by the number of patients to obtain the average cost per study patient. Consequently, a measure of dispersion is not available for these outcomes.

    Time frame: 12 Months

  5. Economic Cost Implications - Cost of Bleeding Hospitalization for 1000 LVAD Implants Over the First-year Post-implant

    Cost of bleeding episodes was calculated based on a previously published economic model, adjusted for inflation using the US Bureau of Labor Statistics Medical Consumer Price Index. To ensure uniformity in care practices and relevance of the previously published model, only US subjects were included.

    Time frame: 12 Months

07

Results

Posted Mar 27, 2025
Limitations and caveats
We excluded patients with early surgical complications or those that required mechanical support devices in addition to the implanted LVAD, or when investigators deemed aspirin therapy necessary.

Participant flow

The study enrolled and randomized 628 subjects at 51 sites. Enrollment took place between July 2020 and September 2022, with the last subject follow up concluding in August 2023.

Modified Intent-to-Treat (mITT)
Participant flow — Modified Intent-to-Treat (mITT)
MilestonePlacebo ArmAspirin Arm
Started314314
Completed296293
Not completed1821
Withdrew: Death12
Withdrew: Withdrawal by subject97
Withdrew: Transitioned to open label812
Principal Analysis
Participant flow — Principal Analysis
MilestonePlacebo ArmAspirin Arm
Started296293
Completed271273
Not completed2520
Withdrew: Withdrawn without primary end point event2520

Outcome measures

PrimaryPowered Primary Endpoint of Survival Free of Non-surgical Major Hemocompatibility Related Adverse Events

The primary end point was a composite of survival free of non-surgical major hemocompatibility related adverse events (specifically stroke, pump thrombosis, major non-surgical bleeding, and arterial peripheral thromboembolism) at 1-year post implant.

Time frame:
12 Months
Reported as:
Count of participants · Participants
Powered Primary Endpoint of Survival Free of Non-surgical Major Hemocompatibility Related Adverse Events
ParticipantsPlacebo Arm (Principal Analysis Population)Aspirin Arm (Principal Analysis Population)
Powered Primary Endpoint of Survival Free of Non-surgical Major Hemocompatibility Related Adverse Events201186
Statistical analysis
  • Placebo Arm (Principal Analysis Population) vs Aspirin Arm (Principal Analysis Population) · Farrington-Manning risk difference · p = <0.0001 · Risk difference (rd): 6
SecondaryRates of Non-surgical Major Hemorrhagic Events

The rate of non-surgical hemorrhagic events were compared between the two arms of the study. Non-surgical Major Hemorrhagic events: Hemorrhagic event rate per patient year was calculated by dividing all non-surgical bleeding events and hemorrhagic stroke events by the cumulative years of study exposure.

Time frame:
Through Study Completion with a Median Follow up of 14 Months
Reported as:
Number · Event Per 100 Patient-Year
Rates of Non-surgical Major Hemorrhagic Events
Event Per 100 Patient-YearPlacebo Arm (Modified Intent-to-treat Population)Aspirin Arm (Modified Intent-to-treat Population)
All Non-surgical Major Hemorrhagic events26.240.7
Bleeding25.9339.53
Hemorrhagic Stroke0.270.85
Ischemic Stroke with Hemorrhagic Conversion0.000.28
SecondaryRates of Bleeding Events

The bleeding rate was calculated by dividing the number of bleeding events by the cumulative duration of study exposure (years of support).

Time frame:
Through Study Completion with a Median Follow up of 14 Months
Reported as:
Number · Event Per 100 Patient-Year
Rates of Bleeding Events
Event Per 100 Patient-YearPlacebo Arm (Modified Intent-to-treat Population)Aspirin Arm (Modified Intent-to-treat Population)
All Bleeding Events25.9239.53
Moderate Bleeding8.4613.65
Severe Bleeding17.4725.88
GI Bleeding13.1021.61
Fatal Bleeding0.550.85
SecondaryRates of Non-surgical Major Thrombotic Events

The rates of non-surgical major thrombotic events was compared between the two arms of the study. The thrombotic event rate per patient year was calculated by dividing the number of non-surgical ischemic strokes, pump thrombosis and arterial peripheral thromboembolic events by the cumulative years of study exposure

Time frame:
Through Study Completion with a Median Follow up of 14 Months
Reported as:
Number · Event Per 100 Patient-Year
Rates of Non-surgical Major Thrombotic Events
Event Per 100 Patient-YearPlacebo Arm (Modified Intent-to-treat Population)Aspirin Arm (Modified Intent-to-treat Population)
All Major Thrombotic events1.642.84
Ischemic Stroke without Hemorrhagic Conversion1.642.56
Device Thrombosis0.000.00
Arterial Peripheral Thromboembolism0.000.00
SecondaryRates of Stroke

The stroke rate was calculated based on the number of strokes experienced by subjects, 14 days or more after device implant, and while on their treatment assignment, divided by the cumulative duration of study exposure (years of support).

Time frame:
Through Study Completion with a Median Follow up of 14 Months
Reported as:
Number · Event Per 100 Patient-Year
Rates of Stroke
Event Per 100 Patient-YearPlacebo Arm (Modified Intent-to-treat Population)Aspirin Arm (Modified Intent-to-treat Population)
All Stroke1.913.70
Debilitating Stroke (MRS>3)0.820.57
Non-Debilitating Stroke (MRS<=3)1.093.13
SecondarySurvival Rates

The overall survival rate was analyzed using a Kaplan-Meier analysis and the treatment groups were compared using log-rank test. Survival was calculated starting at 14 days post implant.

Time frame:
24 Months
Reported as:
Number · Percentage of Participants
Survival Rates
Percentage of ParticipantsPlacebo Arm (Modified Intent-to-treat Population)Aspirin Arm (Modified Intent-to-treat Population)
Survival Rates9389.7
SecondaryRisk of Non-Surgical Bleeding Events

Risk of non-surgical bleeding events was analyzed using a Kaplan-Meier analysis. The treatment groups were compared using a log-rank test.

Time frame:
24 Months
Reported as:
Number · Percentage of Participants
Risk of Non-Surgical Bleeding Events
Percentage of ParticipantsPlacebo Arm (Modified Intent-to-treat Population)Aspirin Arm (Modified Intent-to-treat Population)
Risk of Non-Surgical Bleeding Events30.042.4
Other pre-specifiedRate of Rehospitalization

This study assessed changes in the rehospitalization as a result of removal of antiplatelet therapy from the antithrombotic regimen.

Time frame:
Through Study Completion with a Median Follow up of 14 Months
Reported as:
Number · Event Per 100 Patient-Year
Rate of Rehospitalization
Event Per 100 Patient-YearPlacebo Arm (Modified Intent-to-treat Population)Aspirin Arm (Modified Intent-to-treat Population)
Hemocompatibility Related0.150.28
Major Infection0.340.36
Hypertension0.030.02
Cardiovascular Related0.330.33
Non-cardiovascular organ dysfunction0.060.05
Neurologic dysfunction (excluding stroke, TIA)0.010.02
Other0.410.42
Other pre-specifiedEconomic Cost Implications - Total Estimated Cost for Bleeding Events (CMS Cost Basis)

Cost of bleeding episodes was calculated based on a previously published economic model, adjusted for inflation using the US Bureau of Labor Statistics Medical Consumer Price Index. To ensure uniformity in care practices and relevance of the previously published model, only US subjects were included.

Time frame:
12 Months
Reported as:
Number · USD
Economic Cost Implications - Total Estimated Cost for Bleeding Events (CMS Cost Basis)
USDPlacebo Arm (Modified Intent-to-treat Population)Aspirin Arm (Modified Intent-to-treat Population)
Economic Cost Implications - Total Estimated Cost for Bleeding Events (CMS Cost Basis)546,947927,040
Other pre-specifiedEconomic Cost Implications - Average Cost Per Bleeding Event

These values were derived by dividing the total estimated cost for bleeding events by the number of events to determine the average cost per bleeding event. Consequently, a measure of dispersion is not available for these outcomes.

Time frame:
12 Months
Reported as:
Number · USD
Economic Cost Implications - Average Cost Per Bleeding Event
USDPlacebo Arm (Modified Intent-to-treat Population)Aspirin Arm (Modified Intent-to-treat Population)
Economic Cost Implications - Average Cost Per Bleeding Event13,67413,836
Other pre-specifiedEconomic Cost Implications - Average Cost Per Study Patient Over the First-year Post-implant

These values were derived by dividing the total estimated cost for bleeding events by the number of patients to obtain the average cost per study patient. Consequently, a measure of dispersion is not available for these outcomes.

Time frame:
12 Months
Reported as:
Number · USD
Economic Cost Implications - Average Cost Per Study Patient Over the First-year Post-implant
USDPlacebo Arm (Modified Intent-to-treat Population)Aspirin Arm (Modified Intent-to-treat Population)
Economic Cost Implications - Average Cost Per Study Patient Over the First-year Post-implant2,2143,799
Other pre-specifiedEconomic Cost Implications - Cost of Bleeding Hospitalization for 1000 LVAD Implants Over the First-year Post-implant

Cost of bleeding episodes was calculated based on a previously published economic model, adjusted for inflation using the US Bureau of Labor Statistics Medical Consumer Price Index. To ensure uniformity in care practices and relevance of the previously published model, only US subjects were included.

Time frame:
12 Months
Reported as:
Number · USD/1000 implants/1 year
Economic Cost Implications - Cost of Bleeding Hospitalization for 1000 LVAD Implants Over the First-year Post-implant
USD/1000 implants/1 yearPlacebo Arm (Modified Intent-to-treat Population)Aspirin Arm (Modified Intent-to-treat Population)
Economic Cost Implications - Cost of Bleeding Hospitalization for 1000 LVAD Implants Over the First-year Post-implant2,214,3623,799,344

Adverse events

Collected over All adverse events occurring through study completion (median follow up of 14 months) were collected.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Arm (Modified Intent-to-treat Population)21/296 (7.1%)208/296 (70.3%)200/296 (67.6%)
Aspirin Arm (Modified Intent-to-treat Population)22/293 (7.5%)223/293 (76.1%)181/293 (61.8%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventPlacebo Arm (Modified Intent-to-treat Population)Aspirin Arm (Modified Intent-to-treat Population)
Major InfectionInfections and infestations99/296116/293
BleedingBlood and lymphatic system disorders68/296100/293
Cardiac ArrhythmiaCardiac disorders44/29641/293
Cardiac DisordersCardiac disorders33/29635/293
Metabolism And Nutrition DisordersMetabolism and nutrition disorders32/29633/293
General Disorders And Administration Site ConditionsGastrointestinal disorders31/29624/293
Nervous System DisordersNervous system disorders22/29626/293
Neurologic DysfunctionNervous system disorders25/29621/293
Respiratory, Thoracic And Mediastinal DisordersRespiratory, thoracic and mediastinal disorders25/29624/293
Gastrointestinal DisordersGastrointestinal disorders24/29613/293
Most frequent other events
Showing 10 of 24
Most frequent other events
EventPlacebo Arm (Modified Intent-to-treat Population)Aspirin Arm (Modified Intent-to-treat Population)
Major InfectionInfections and infestations94/29692/293
Metabolism And Nutrition DisordersMetabolism and nutrition disorders43/29633/293
Cardiac DisordersCardiac disorders42/29623/293
Nervous System DisordersNervous system disorders40/29626/293
Vascular DisordersVascular disorders36/29639/293
General Disorders And Administration Site ConditionsGeneral disorders34/29621/293
InvestigationsInvestigations25/29629/293
Respiratory, Thoracic And Mediastinal DisordersRespiratory, thoracic and mediastinal disorders25/29627/293
Injury, Poisoning And Procedural ComplicationsInjury, poisoning and procedural complications20/29624/293
Gastrointestinal DisordersGastrointestinal disorders21/29618/293

Baseline characteristics

The Modified Intention to Treat Population (mITT) included all randomized subjects with the following exception: 1. Subjects who experienced a surgical adverse event, defined as ≤14 days post-implant, requiring investigator mandated antiplatelet therapy; 2. Subjects who expired, are transplanted, or withdrawn within 14 days of implant.

Age, Continuous
Age, Continuous(years)Placebo ArmAspirin ArmTotal
Mean57.6 ± 12.856.5 ± 14.457.1 ± 13.6
Sex: Female, Male
Sex: Female, Male(Participants)Placebo ArmAspirin ArmTotal
Female7261133
Male224232456
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo ArmAspirin ArmTotal
American Indian or Alaska Native000
Asian13922
Native Hawaiian or Other Pacific Islander235
Black or African American9384177
White179181360
More than one race336
Unknown or Not Reported61319
Heart Failure Etiology
Heart Failure Etiology(Participants)Placebo ArmAspirin ArmTotal
Ischemic Cardiomyopathy106101207
Idiopathic Cardiomyopathy6863131
Dilated Cardiomyopathy8681167
Other364884
Intended Use
Intended Use(Participants)Placebo ArmAspirin ArmTotal
Bridge to Transplantation5658114
Bridge to Candidacy for Transplantation465096
Destination Therapy180174354
Bridge to Recovery141125
INTERMACS Profile
INTERMACS Profile(Participants)Placebo ArmAspirin ArmTotal
1121830
27675151
3133133266
46654120
56814
6358
7000
New York Heart Association (NYHA) Class
New York Heart Association (NYHA) Class(Participants)Placebo ArmAspirin ArmTotal
Class II325
Class IIIA272956
Class IIIB403878
Class IV226224450
Region of Enrollment
Region of Enrollment(Participants)Placebo ArmAspirin ArmTotal
North America251248499
Other454590
08

Study locations

51 sites
  • Baptist Health Medical Center
    Little Rock, Arkansas 72205, United States
  • University of California, San Diego
    La Jolla, California 92037, United States
  • Stanford University Medical Center
    Palo Alto, California 94304, United States
  • Sharp Memorial Hospital
    San Diego, California 92123, United States
  • California Pacific Medical Center - Van Ness Campus
    San Francisco, California 94109, United States
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • Washington Hospital Center
    Washington, District of Columbia 20010, United States
  • Miami Transplant Institute - Jackson Memorial
    Miami, Florida 33136, United States
  • AdventHealth Orlando
    Orlando, Florida 32804, United States
  • Piedmont Heart Institute
    Atlanta, Georgia 30309, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Advocate Christ Medical Center
    Oak Lawn, Illinois 60453, United States
  • St. Vincent Hospital
    Indianapolis, Indiana 46240, United States
  • Kansas University Medical Center
    Kansas City, Kansas 66160, United States
  • Ochsner Medical Center
    New Orleans, Louisiana 70121, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Minneapolis Heart Institute
    Minneapolis, Minnesota 55407, United States
  • University of Minnesota Medical Center Fairview
    Minneapolis, Minnesota 55455, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • New York-Presbyterian/Columbia University Medical Center
    New York, New York 10032, United States
  • Montefiore Medical Center - Moses Division
    New York, New York 10467, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Carolinas Medical Center
    Charlotte, North Carolina 28203, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • The Christ Hospital
    Cincinnati, Ohio 45219, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Integris Baptist Medical Center
    Oklahoma City, Oklahoma 73112, United States
  • Providence Heart & Vascular Institute
    Portland, Oregon 97225, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Allegheny General Hospital - ASRI
    Pittsburgh, Pennsylvania 15212, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Baylor University Hospital
    Dallas, Texas 75246, United States
  • Memorial Hermann Hospital
    Houston, Texas 77030, United States
  • University of Utah Hospital
    Salt Lake City, Utah 84132, United States
  • Aurora Medical Group
    Milwaukee, Wisconsin 53215, United States
  • St. Vincent's Hospital, Sydney
    Darlinghurst, New 2010, Australia
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • AKH - Wien
    Vienna, 1090, Austria
  • University of Alberta Hospital
    Edmonton, T6G 2B7, Canada
  • IKEM Prague
    Prague, Central Bohemia 140 24, Czechia
  • Hopital Haut Leveque
    Pessac, 33600, France
  • CHU Rangueil Toulouse
    Toulouse, 31000, France
  • Ospedale San Raffaele
    Milan, Italy
  • National Research Center for Cardiac Surgery
    Astana, 10000, Kazakhstan
  • Queen Elizabeth Hospital
    Birmingham, B15 2GW, United Kingdom
09

References and documents

Publications

  • Mehra MR, Netuka I, Uriel N, Katz JN, Pagani FD, Jorde UP, Gustafsson F, Connors JM, Ivak P, Cowger J, Ransom J, Bansal A, Takeda K, Agarwal R, Byku M, Givertz MM, Bitar A, Hall S, Zimpfer D, Vega JD, Kanwar MK, Saeed O, Goldstein DJ, Cogswell R, Sheikh FH, Danter M, Pya Y, Phancao A, Henderson J, Crandall DL, Sundareswaran K, Soltesz E, Estep JD; ARIES-HM3 Investigators. Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial. JAMA. 2023 Dec 12;330(22):2171-2181. doi: 10.1001/jama.2023.23204. PubMed 37950897 ↗
  • Gustafsson F, Uriel N, Netuka I, Katz JN, Pagani FD, Connors JM, Jorde UP, Zimpfer D, Pya Y, Conway J, Anyanwu A, Scandroglio AM, Sulemanjee N, Atluri P, Keebler M, Selzman CH, Alexis JD, Hayward C, Henderson J, Dirckx N, Gazzola C, Mehra MR; ARIES Investigators. Aspirin and Hemocompatibility After LVAD Implantation in Patients With Atherosclerotic Vascular Disease: A Secondary Analysis From the ARIES-HM3 Randomized Clinical Trial. JAMA Cardiol. 2025 Mar 1;10(3):235-242. doi: 10.1001/jamacardio.2024.4849. PubMed 39774588 ↗
  • Mehra MR, Crandall DL, Gustafsson F, Jorde UP, Katz JN, Netuka I, Uriel N, Connors JM, Sood P, Heatley G, Pagani FD. Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trial. Eur J Heart Fail. 2021 Jul;23(7):1226-1237. doi: 10.1002/ejhf.2275. Epub 2021 Jul 1. PubMed 34142415 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — To be determined

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Aug 2023, 36 months.

Results were first posted in Mar 2025, 1 year 7 months after primary completion.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 62. This study's 36 months is close to that.

Counting every sponsor, half of 1,354 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2019
First posted
Aug 28, 2019
StartActual
Jul 14, 2020
Primary completionActual
Aug 10, 2023
CompletionActual
Aug 10, 2023
Results first posted
Mar 27, 2025
Last update
Mar 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04069156
Responsible party
Sponsor
First posted
Aug 28, 2019
Start date
Jul 14, 2020
Primary completion
Aug 10, 2023
Completion
Aug 10, 2023
Results posted
Mar 27, 2025
Last update
Mar 27, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion